ATE444363T1 - Il-21-antagonisten - Google Patents

Il-21-antagonisten

Info

Publication number
ATE444363T1
ATE444363T1 AT02773925T AT02773925T ATE444363T1 AT E444363 T1 ATE444363 T1 AT E444363T1 AT 02773925 T AT02773925 T AT 02773925T AT 02773925 T AT02773925 T AT 02773925T AT E444363 T1 ATE444363 T1 AT E444363T1
Authority
AT
Austria
Prior art keywords
antagonists
helix
mutations
polypeptides
specificity
Prior art date
Application number
AT02773925T
Other languages
English (en)
Inventor
Scott Presnell
James West
Julia Novak
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE444363T1 publication Critical patent/ATE444363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02773925T 2001-11-05 2002-10-28 Il-21-antagonisten ATE444363T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33758601P 2001-11-05 2001-11-05
PCT/US2002/034502 WO2003040313A2 (en) 2001-11-05 2002-10-28 Il-21 antagonists

Publications (1)

Publication Number Publication Date
ATE444363T1 true ATE444363T1 (de) 2009-10-15

Family

ID=23321131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773925T ATE444363T1 (de) 2001-11-05 2002-10-28 Il-21-antagonisten

Country Status (11)

Country Link
US (3) US6929932B2 (de)
EP (2) EP2130919A1 (de)
JP (2) JP2005508179A (de)
AT (1) ATE444363T1 (de)
AU (1) AU2002336676A1 (de)
CA (1) CA2465156C (de)
DE (1) DE60233888D1 (de)
DK (1) DK1451322T3 (de)
ES (1) ES2334338T3 (de)
MX (1) MXPA04004167A (de)
WO (1) WO2003040313A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
EP1603674B1 (de) * 2003-02-05 2016-01-06 Iquum, Inc. Probenverarbeitung
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
EP1641422A4 (de) * 2003-06-19 2007-08-22 Centocor Inc Interleukin-21 analoga
EP1673387B1 (de) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21-derivate
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP2641611A3 (de) * 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
WO2005052139A2 (en) * 2003-11-19 2005-06-09 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method of inducing memory b cell development and terminal differentiation
WO2005067956A2 (en) * 2004-01-15 2005-07-28 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
KR20070014181A (ko) * 2004-05-19 2007-01-31 와이어쓰 면역글로불린 생성 및 아토피 질환의 조절
ATE389960T1 (de) * 2004-06-30 2008-04-15 Tyco Electronics Nederland Bv Verbinder für elektronische bauteile
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
DE602006020032D1 (de) * 2005-04-18 2011-03-24 Novo Nordisk As Il-21-varianten
RU2420308C2 (ru) * 2005-06-06 2011-06-10 Ново Нордикс А/С Стабилизированные композиции ил-21
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
US20080003564A1 (en) * 2006-02-14 2008-01-03 Iquum, Inc. Sample processing
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
EP2109620B1 (de) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21-varianten mit geänderter bindung an den il-21-rezeptor
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
WO2010055366A2 (en) 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
US20110245107A1 (en) 2008-01-18 2011-10-06 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, amd modulation of human th17 cells
AR071885A1 (es) * 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
AR072136A1 (es) * 2008-05-23 2010-08-11 Wyeth Corp Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
ES2784830T3 (es) 2008-10-08 2020-10-01 Cambridge Entpr Ltd Métodos para el diagnóstico y tratamiento de enfermedad autoinmune como consecuencia de esclerosis múltiple
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
WO2012012531A2 (en) * 2010-07-20 2012-01-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
RS60050B1 (sr) * 2011-01-18 2020-04-30 Bioniz Llc Kompozicije za modulaciju aktivnosti gama-c-citokina
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CA2978449A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
ES2884357T3 (es) 2015-10-09 2021-12-10 Bioniz Llc Modulación de la actividad de las citocinas gamma-c
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
MA56289B1 (fr) 2017-08-03 2022-04-29 Amgen Inc Mutéines d'interleukine-21 et méthodes de traitement
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
GB2623654A (en) 2021-05-19 2024-04-24 Asher Biotherapeutics Inc Il-21 polypeptides and targeted constructs

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615974A (en) 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
ATE54167T1 (de) 1984-12-06 1990-07-15 Fina Research Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
DE721983T1 (de) 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
EP0749319A1 (de) 1992-09-14 1996-12-27 Pfizer Inc. Immortalisierte zellen und verwendungen dafür
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
JP2000500014A (ja) 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
CA2261151C (en) 1996-07-17 2003-09-16 Zymogenetics, Inc. Transformation of pichia methanolica
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US9418201B1 (en) 2015-11-19 2016-08-16 International Business Machines Corporation Integration of functional analysis and common path pessimism removal in static timing analysis

Also Published As

Publication number Publication date
MXPA04004167A (es) 2004-07-08
EP1451322B1 (de) 2009-09-30
EP2130919A1 (de) 2009-12-09
WO2003040313A2 (en) 2003-05-15
EP1451322A4 (de) 2005-02-02
JP2005508179A (ja) 2005-03-31
EP1451322A2 (de) 2004-09-01
ES2334338T3 (es) 2010-03-09
JP2010207238A (ja) 2010-09-24
AU2002336676A1 (en) 2003-05-19
US7186805B2 (en) 2007-03-06
US20050244930A1 (en) 2005-11-03
CA2465156A1 (en) 2003-05-15
DK1451322T3 (da) 2010-02-01
DE60233888D1 (de) 2009-11-12
CA2465156C (en) 2011-10-18
US6929932B2 (en) 2005-08-16
US20030134390A1 (en) 2003-07-17
US20070166796A1 (en) 2007-07-19
WO2003040313A3 (en) 2003-09-25
US7410780B2 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
ATE444363T1 (de) Il-21-antagonisten
DE10192353T1 (de) Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung
CY2016004I2 (el) ΜΟΡΙΑ ΠΡΟΣΔΕΣΗΣ ΑΝΤΙΓΟΝΟΥ ΜΕ ΑΥΞΗΜΕΝΗ ΣΥΓΓΕΝΕΙΑ ΠΡΟΣΔΕΣΗΣ ΣΤΟΝ ΥΠΟΔΟΧΕΑ Fc ΚΑΙ ΛΕΙΤΟΥΡΓΙΑ ΤΕΛΕΣΤΗ
CY1118951T1 (el) Χρηση αντισωματων υποδοχεα ιντερλευκινης-4 και συνθεσεις αυτων
HK1086598A1 (en) Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof
ATE534457T1 (de) Fraktalstruktur zum mischen von mindestens zwei fluiden
NL1021695A1 (nl) Thermisch stabiele mengsels van een in hoge mate paraffinische destillaatbrandstofcomponent en een gebruikelijke destillaatbrandstofcomponent.
EP2949658A3 (de) Spezifisch an HGF-Rezeptor (cMet) bindende Peptide und deren Verwendung
DK1421224T3 (da) Polypeptider med cellobiohydrolase I aktivitet og polynukleotider der koder for samme
NO20035173L (no) TACI-immunoglobulinfusjonsproteiner
HUP0102005A2 (hu) CD23 elleni antitestek, ezek származékai, és gyógyászati alkalmazásuk
DE60132709D1 (de) Bestimmung der wirksamen zusammensetzung von kohlenwasserstoffgasen
HK1120556A1 (en) Neurotrophic factors
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2005019270A3 (en) Endotheliase-2 ligands
IS6874A (is) 3,7-díasabísýkló[3.3.0]oktön og notkun þeirra í meðhöndlun á hjartsláttarglöpum
ITRM20030259A0 (it) Catalizzatore multistrato, procedimento per la sua preparazione e suouso per l'ossidazione parziale di idrocarburi in fase gassosa.
WO2002002630A3 (en) Hcn polypeptides and polynucleotides and their use in therapy
JP2004511237A5 (de)
ATE270551T1 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol
TWI319404B (en) Novel orff and orff' polypeptides, nucleic acid molecules encoding the polypeptides and applications thereof
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
AU2003213676A1 (en) Novel nucleic acid molecules and polypeptides encoding baboon tafi
ATE316421T1 (de) P-funktionalisierte amine n-haltiger aromaten, deren herstellung und ihre verwendung in katalytischen reaktionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1451322

Country of ref document: EP